Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith, Sean Parker, Alyn H. Morice et al.|The Lancet Respiratory Medicine|2020

Cited by 224